Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

Eric Tran, Simon Turcotte, Alena Gros, Paul F. Robbins, Yong Chen Lu, Mark E. Dudley, John R. Wunderlich, Robert P. Somerville, Katherine Hogan, Christian S. Hinrichs, Maria R. Parkhurst, James C. Yang, Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review

1111 Scopus citations

Abstract

Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 (TH1) cells recognizing a mutation in erbb2 interacting protein (ERBB2IP) expressed by the cancer. After adoptive transfer of TIL containing about 25% mutation-specific polyfunctional TH1 cells, the patient achieved a decrease in target lesions with prolonged stabilization of disease. Upon disease progression, the patient was retreated with a >95% pure population of mutation-reactive T H1 cells and again experienced tumor regression. These results provide evidence that a CD4+ T cell response against a mutated antigen can be harnessed to mediate regression of a metastatic epithelial cancer.

Original languageEnglish (US)
Pages (from-to)641-645
Number of pages5
JournalScience
Volume344
Issue number6184
DOIs
StatePublished - 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer'. Together they form a unique fingerprint.

Cite this